Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 7/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.39 |
| ▸ | TAS1R2 | Q8TE23 | 3/20 | 0.39 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24514487 | 1.00 | EPHX1 (0.46) | EPHX1NPC1SMN1; SMN2EPHX2RAB9A | |
| SCHEMBL22991205 | 0.98 | EPHX1 (0.42) | EPHX1NPC1SMN1; SMN2EPHX2RAB9A | |
| SCHEMBL15540703 | 0.80 | EPHX1 (0.50) | EPHX1NPC1SMN1; SMN2EPHX2RAB9A | |
| SCHEMBL4434059 | 0.77 | EPHX1 (0.46) | EPHX1NPC1SMN1; SMN2EPHX2RAB9A | |
| SCHEMBL28199824 | 0.76 | EPHX1 (0.46) | EPHX1NPC1SMN1; SMN2EPHX2RAB9A | |
| SCHEMBL3070705 | 0.76 | EPHX1 (0.46) | EPHX1NPC1SMN1; SMN2EPHX2RAB9A | |
| SCHEMBL6636667 | 0.76 | PDK1 (0.46) | EPHX1NPC1SMN1; SMN2EPHX2RAB9A | |
| Acetic Acid SCHEMBL17714091 | 0.75 | ALDH1A1 (0.63) | EPHX1NPC1SMN1; SMN2EPHX2RAB9A | |
| SCHEMBL3038208 | 0.75 | EPHX1 (0.64) | EPHX1NPC1SMN1; SMN2EPHX2RAB9A | |
| SCHEMBL16317723 | 0.75 | EPHX1 (0.64) | EPHX1NPC1SMN1; SMN2EPHX2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1996554-B1 | SIGMA RECEPTOR INHIBITORS | ESTEVE LABOR DR (ES) | 2012-08-08 | — | — | EP | disclosed |
| US-20120059006-A1 | SIGMA RECEPTOR INHIBITORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-03-08 | — | — | US | disclosed |
| US-20120059006-A1 | SIGMA RECEPTOR INHIBITORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-03-08 | — | — | US | disclosed |
| US-8088812-B2 | Sigma receptor inhibitors | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-01-03 | — | — | US | disclosed |
| US-20090247525-A1 | SIGMA RECEPTOR INHIBITORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-10-01 | — | — | US | disclosed |
| WO-2007098963-A1 | SIGMA RECEPTOR INHIBITORS | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2007-09-07 | — | — | WO | disclosed |
| US-7045526-B2 | Substituted 4-amino-2-aryl-tetrahydroquinazolines, their preparation, their use and pharmaceutical preparations comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-05-16 | — | — | US | disclosed |
| US-6660746-B1 | Cardiovascular disorders | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-12-09 | — | — | US | disclosed |
| US-5948780-A | ADMINISTERING A METALLOPROTEINASE INHIBITOR | WARNER-LAMBERT COMPANY (US) | 1999-09-07 | — | — | US | disclosed |
| US-5672615-A | MATRIX-DEGRADING METALLOPROTEINASE INHIBITORS | NOVARTIS CORPORATION (US) | 1997-09-30 | — | — | US | disclosed |
| EP-0061623-A1 | Process for dyeing or printing paper, and cationic phthalocyanine dyes | BASF Aktiengesellschaft (DE) | 1982-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059006-A1 | SIGMA RECEPTOR INHIBITORS | SIGMAR1, TMEM97, OPRK1 | EPHX1 1333/4885NPC1 397/4885SMN1; SMN2 2305/4885 |
| US-20090247525-A1 | SIGMA RECEPTOR INHIBITORS | SIGMAR1, TMEM97, OPRK1 | EPHX1 1333/4885NPC1 397/4885SMN1; SMN2 2305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.